Inhibition of EYA family tyrosine phosphatase activity reveals a therapeutic vulnerability and enhances Menin and DOT1L inhibitor efficacy in KMT2A-rearranged leukemia [0.03%]
EYA家族酪氨酸磷酸酶活性抑制可揭示出治疗弱点并增强MENIN和DOT1L抑制剂在KMT2A重排白血病中的疗效
Lola Badmus,Nicholas J Achille,Shubin Zhang et al.
Lola Badmus et al.
MLL (KMT2A)-rearranged leukemia (MLL-r) is a highly aggressive hematologic malignancy driven by transcriptional dysregulation. Here, we identify EYA family phosphatase activity, particularly EYA1 and EYA3, as key vulnerabilities in MLL-r le...
KMT2A alterations in acute myeloid leukemia: a proposed genetic risk model and transplantation outcomes [0.03%]
急性髓系白血病中KMT2A基因改变的遗传风险模型及移植预后研究
Li Chen,Jianfeng Li,Yongmei Zhu et al.
Li Chen et al.
KMT2A-altered acute myeloid leukemia (AML) comprises rearrangements (KMT2A-r), partial tandem duplications (KMT2A-PTD), and dual alterations (KMT2A-r/PTD). In this study of 125 patients, these subgroups exhibited distinct molecular profiles...
Anti-tumor vaccine efficacy depends on adjuvant type and associates with induced IgG subclass and glycosylation profiles [0.03%]
抗肿瘤疫苗的效力取决于佐剂的类型并与诱导的IgG亚类和糖基化谱型相关
Selina Lehrian,Anna Wasynczuk,Janina Petry et al.
Selina Lehrian et al.
Vaccination with tumor-(neo) antigen plus adjuvant is emerging as a promising cancer-therapy. However, as different adjuvants induce distinct immune cell and antibody (Ab) responses, selecting the right adjuvants remains challenging. Here, ...
Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed/refractory multiple myeloma [0.03%]
靶向BCMA的CAR-T细胞疗法Zevo-cilta-cel治疗复发/难治多发性骨髓瘤II期临床试验
Wenming Chen,Chengcheng Fu,Baijun Fang et al.
Wenming Chen et al.
Background: Zevorcabtagene autoleucel (zevor-cel) is a fully human autologous CAR T-cell therapy targeting B-cell maturation antigen approved in China since 2024 for patients with relapsed/refractory multiple myeloma (RRM...
Brain metastasis-associated cancer fibroblasts drive tumor progression and therapeutic resistance through IL26 and CX3CL1 signaling in non-small-cell lung cancer [0.03%]
非小细胞肺癌相关脑转移癌纤维母细胞通过IL26和CX3CL1信号促进肿瘤进展及治疗抵抗
S M Abdus Salam,Eshrat Jahan,Eun-Jung Ahn et al.
S M Abdus Salam et al.
Brain metastases (BM) from non-small cell lung cancer (NSCLC) represent a significant clinical challenge, characterized by poor prognosis and treatment resistance. While cancer-associated fibroblasts (CAFs) are recognized as crucial compone...
Revisiting thrombophilia testing: leveraging next-generation sequencing for precision in VTE management [0.03%]
重温血栓病检测：利用下一代测序技术提高静脉血栓栓塞管理的精准性
Ilham Youssry,Nardeen Ayad
Ilham Youssry
Venous thromboembolism (VTE) remains a significant cause of morbidity and mortality, particularly among individuals with inherited thrombophilia. Despite the widespread use of thrombophilia testing, its clinical value is often questioned du...
Novel tumor-infiltrating lymphocytes therapy in solid tumors: latest updates from 2025 ASCO annual meeting [0.03%]
2025年ASCO年会固体制剂肿瘤浸润淋巴细胞治疗最新进展
Yanan Ma,Xuan Su,Huijing Feng
Yanan Ma
Tumor-infiltrating lymphocyte (TIL) therapy, a highly promising form of adoptive cell therapy (ACT), has demonstrated success in treating advanced melanoma. Notably, innovative TIL-based monotherapies and combination regimens have provided ...
FGL1-mediated lymph node metastasis in stage T1 non-small cell lung cancer: therapeutic targeting [0.03%]
FGRL1介导的T1期非小细胞肺癌淋巴结转移及其治疗靶向性研究
Xi-Yang Tang,Run-Ze Zhang,Zhi-Bo Feng et al.
Xi-Yang Tang et al.
Background: Approximately 30% of patients with stage T1 non-small cell lung cancer (NSCLC) have mediastinal (N2) lymph node metastasis; however, the underlying mechanism remains unclear. ...
Transforming cancer immunotherapy: integration of distinct immune-based approaches as redefined dual immunotherapy with potential third-sensitizer [0.03%]
重塑癌症免疫治疗：作为重新定义的双重免疫治疗集成不同基于免疫的方法及潜在的第三增敏疗法
Yuqian Wang,Cheng Jiang,Huiling Zhou et al.
Yuqian Wang et al.
This review introduces a paradigm-shifting concept of Dual Distinct Immunotherapy (DDI), which strategically integrates two distinct immunotherapeutic modalities to overcome the limitations of current monotherapies and dual immune checkpoin...
Tumor-priming CD8+ natural killer T-like cells as an efficient novel cell therapy for relapsed/refractory multiple myeloma [0.03%]
肿瘤预激CD8⁺自然杀伤T类细胞作为治疗复发/难治性多发性骨髓瘤的一种有效新型的细胞疗法
Juheon Lee,Eunjeong Choi,Bohwa Han et al.
Juheon Lee et al.
Background: Relapsed and refractory multiple myeloma (RRMM) remains a major clinical challenge, as most patients eventually relapse following standard treatments and are left with limited therapeutic options. Although b-c...